A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving

Table 2 Assessment of withdrawal craving (with repeated measures) in 14 phases (days)

Group	N = 35 Buprenorphine Mean ± SD	N = 30 Bupropion Mean ± SD	t value	df	P value	Power
Day	N = 35 Buprenorphine Mean ± SD	N = 30 Bupropion Mean ± SD	t value	df	P value	Power
Day 1	6.09 ± 2.005	6.6 ± 1.98	−1.04	63	0.303	0.17
Day 2	5.57 ± 1.85	6 ± 1.98	−0. 9	63	0.371	0.14
Day 3	4.71 ± 2.08	5.7 ± 2.28	−1.823	63	0.073	0.43
Day 4	4.29 ± 2.08	4.73 ± 2.35	−0.826	63	0.412	0. 12
Day 5	3.85 ± 2.07	4.63 ± 2.19	−1.466	63	0.148	0. 3
Day 6	3.68 ± 1.97	4.63 ± 2.19	−1.902	63	0.062	0.44
Day 7	2.63 ± 1.78	4. 1 ± 2.56	–	–	0.028*	0.74
Day 8	2.31 ± 1.76	3.97 ± 1.94	−3.599	63	0.001	0.94
Day 9	1.8 ± 1.75	3. 4 ± 2.03	−3.42	63	0.001	0.91
Day 10	1.77 ± 1.93	3.23 ± 2.49	−2.668	63	0.01	0.73
Day 11	1.68 ± 1.73	2.7 ± 2.41	−1.97	63	0.053	0.47
Day 12	1.77 ± 2.16	2.23 ± 2.08	−0.875	63	0.385	0.14
Day 13	0.91 ± 1.59	1.93 ± 2.18	−2.169	63	0.034	0.55
Day 14	0.80 ± 1.29	1.7 ± 2.19	–	–	0.069*	0.45
F	49.074	35.792
df	13	13
P value	<0.001	<0.001

*Mann–Whitney test
In the mean of craving between the buprenorphine and bupropion groups, there is a significant difference (F = 6.811, df = 13, power = 0.729, P = 0.011). Abbreviations: df degrees of freedom, SD standard deviation

ISSN: 1745-6215